Tags: Drug.
Velaglucerase alfa (trade name VPRIV) manufactured by Shire plc is a hydrolytic lysosomal glucocerebroside-specific enzyme which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1. It has an identical amino acid sequence to the naturally occurring enzyme. It was approved for use by the U.S. Food and Drug Administration (FDA) on February 26 2010.